A double-blind twelve-week investigation of mazindol, a new anorexic agent, was carried out in obese patients with stable cardiac disease. The drug was administered in a dosage of 1 mg three times daily, leading to a significant (p < 0·001) loss of body weight (9·8 lbs). The underlying cardiac disease was not adversely affected.
Get full access to this article
View all access options for this article.
References
1.
DeFeliceEABronsteinSBCohenA (1969) Double-blind comparison of placebo and 42–548, a new appetite suppressant, in obese volunteers. Current Therapeutic Research11, 256
2.
GogertyJHHoulihanWGalenHEdenPPenberthyC (1968) Neuropharmacological studies on a imidazoisoindole derivative, 42–548. Federation Proceedings27, 501
3.
SirtoriCRHurwitzAAzarnoffDL (1971) Hyperinsulinemia in humans following damphetamine and mazindol administration. Federation Proceedings20, 316
4.
Metropolitan Life Insurance Company TablesStatistical Bulletin, Metropolitan Life Insurance Company (1959) 40, 1
